Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, CHIEF SCIENTIFIC OFFICER

EVP, CHIEF FINANCIAL OFFICER

PRESIDENT AND CEO

EVP, CHIEF MEDICAL OFFICER

EVP, Chief Medical Officer

EVP, Chief Scientific Officer

President and CEO

EVP, Chief Financial Officer

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase Ã‚Â½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase Ã‚Â½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using i...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-01	Premium	sold	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2024-04-01	Premium	sold	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-04-01	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-04-01	Premium	sold	Premium	Premium	Premium	EVP, CHIEF MEDICAL OFFICER
2024-03-28	Premium	sold	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-03-28	Premium	sold	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2024-03-28	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-03-28	Premium	sold	Premium	Premium	Premium	EVP, CHIEF MEDICAL OFFICER
2024-03-27	Premium	sold	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2024-03-27	Premium	sold	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-03-27	Premium	sold	Premium	Premium	Premium	EVP, CHIEF MEDICAL OFFICER
2024-03-27	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-03-26	Premium	sold	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-03-26	Premium	sold	Premium	Premium	Premium	EVP, CHIEF MEDICAL OFFICER
2024-03-26	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-03-26	Premium	sold	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2024-03-25	Premium	sold	Premium	Premium	Premium	EVP, CHIEF MEDICAL OFFICER
2024-03-25	Premium	sold	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2024-03-25	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-03-25	Premium	sold	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-03-01	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF MEDICAL OFFICER
2024-03-01	Premium	acquired	Premium	Premium	Premium	PRESIDENT AND CEO
2024-03-01	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF FINANCIAL OFFICER
2024-03-01	Premium	acquired	Premium	Premium	Premium	EVP, CHIEF SCIENTIFIC OFFICER
2023-12-11	Premium	acquired	Premium	Premium	Premium	EVP, Chief Medical Officer

RPTX - Repare Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RPTX